Drug development for Alzheimer’s disease: Review
Abstract
Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is considered as one of the most intractable medical problems with heavy social and economic costs. The current drugs for AD, including acetylcholinesterase inhibitors (AChEIs) and memantine, a NMDA receptor antagonist, only temporarily ameliorate cognitive decline, but are unable to stop or reverse the progression of dementia. This paper reviewed the recent advance in AD drug development. The drug discovery programs under clinical trials targeting cholinergic system, α7 nicotinic acetylcholine receptors (nAChRs), N-methyl-d-aspartate receptor (NMDAR), β-secretase, γ-secretase modulators, tau, inflammatory mediators and glucagon-like peptide-1 (GLP-1) were discussed. Though several drug discovery programs are ongoing, the high failure rate is an outstanding issue. Novel techniques and strategies are desperately needed to significantly accelerate this process.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tideglusib, an inhibitor of GSK3β, targets tau hyperphosphorylation required for development of tau tangles.
“Tideglusib (NP-031112 (labeled as 13, Figure 5)), an inhibitor of GSK3β, targets tau hyperphosphorylation, which is required for the development of tau tangles [171,172,173].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [171]
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · see citing works
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676 · see citing works
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · see citing works
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · see citing works
How neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967 · cited 1× · see citing works
“The inflammatory response, which is driven by activated microglia, increases over time as the disease progresses [83].”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · see citing works
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · see citing works
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618 · see citing works
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · see citing works
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · see citing works
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · see citing works
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224 · see citing works
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · cited 2× · see citing works
“The relative risk of AD was largely reduced for those using NSAIDs longer than 24months [84].”
BackgroundAlzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz, C., & Mayeux, R. P. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,180 · see citing works
Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease
Bezprozvanny, I., & Mattson, M. P. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.005 · Cited by 938 · see citing works
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer?s disease
HYND, M. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2004.03.007 · Cited by 938 · see citing works
Burns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859 · see citing works
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · see citing works
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725 · see citing works
A review on cholinesterase inhibitors for Alzheimer’s disease
Anand, P., & Singh, B. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0036-3 · Cited by 722 · see citing works
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672 · see citing works
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568 · see citing works
DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563 · see citing works
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · see citing works
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498 · see citing works
Alzheimer disease therapy—moving from amyloid-β to tau
Giacobini, E., & Gold, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.223 · Cited by 483 · see citing works
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467 · see citing works
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 454 · see citing works
Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427 · cited 2× · see citing works
“The results of phase III trial completed in 2016 failed to suggest benefit of LMTM as an addon treatment for patients with mild-to-moderate AD [77].”
BackgroundDrug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420 · see citing works
Animal Models of Alzheimer Disease
LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419 · see citing works
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. J. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 413 · see citing works
McLaurin, J., Cecal, R., Kierstead, M. E., Tian, X., Phinney, A. L., Manea, M., French, J. E., Lambermon, M. H. L., Darabie, A. A., Brown, M. E., et al. (2002) · Nature Medicine · doi:10.1038/nm790 · Cited by 412 · see citing works
Kennedy, M., Stamford, A., Chen, X., Cox, K., Cumming, J., Dockendorf, M., Egan, M. F., Ereshefsky, L., Hodgson, R., Hyde, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 391 · see citing works
Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., RICHTER, R. W., Soininen, H. S., Thein, S., Shiovitz, T. M., Pilcher, G. D., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374 · see citing works
Weidemann, A., Eggert, S., Reinhard, F. B. M., Vogel, M., Paliga, K., Baier, G., Masters, C. L., Beyreuther, K. T., & Evin, G. M. (2002) · Biochemistry · doi:10.1021/bi015794o · Cited by 352 · see citing works
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351 · see citing works
Winblad, B. G., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., Maguire, R. P., Blennow, K., Lundmark, J., Staufenbiel, M., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70140-0 · Cited by 311 · see citing works
Novák, P., Schmidt, R., Kontseková, E., Žilka, N., Kováčech, B., Škrabana, R., Kazmerova, Z., Katina, S., Fialová, Ľ., Prčina, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 306 · see citing works
Khatoon, S., Grundke, I., & Iqbal, K. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09432.x · Cited by 304 · see citing works
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0189-7 · Cited by 304 · see citing works
Dysfunction of NMDA receptors in Alzheimer’s disease
Zhang, Y., Li, P., Feng, J., & Wu, M. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2546-5 · Cited by 282 · cited 1× · see citing works
“The NMDARs are cationic channels gated by the neurotransmitter glutamate which play an essential role in excitatory transmission, synaptic integration, learning and memory [13].”
BackgroundSafety and biomarker effects of solanezumab in patients with Alzheimer's disease
Farlow, M. R., Arnold, S. E., van Dyck, C. H., Aisen, P. S. S., Snider, B. J., Porsteinsson, A. P., Friedrich, S. W., Dean, R. A., Gonzales, C., Sethuraman, G., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.224 · Cited by 280 · see citing works
Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269 · see citing works
Wiltfang, J., Esselmann, H., Bibl, M., Av, S., Otto, M., Paul, S., Schmidt, B., Klafki, H., Maler, M., Dyrks, T., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00818.x · Cited by 268 · see citing works
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259 · cited 2× · see citing works
“[79] Theunis C, Crespo-Biel N, Gafner V, et al.”
BackgroundEvidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib
Domı́nguez, J. M., Fuertes, A., Orozco, L., del Monte-Millán, M., Delgado, E., & Medina, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.306472 · Cited by 249 · see citing works
Zetterberg, H. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.90 · Cited by 234 · see citing works
Alzheimer’s disease as an inflammatory disease
Bolós, M., Perea, J. R., & Avila, J. (2017) · BioMolecular Concepts · doi:10.1515/bmc-2016-0029 · Cited by 216 · see citing works
Portelius, E., Westman-Brinkmalm, A., Zetterberg, H., & Blennow, K. (2006) · Journal of Proteome Research · doi:10.1021/pr050475v · Cited by 206 · see citing works
Immunotherapy for Alzheimer’s disease: hoops and hurdles
Lemere, C. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-36 · Cited by 196 · see citing works
Gillman, K. W., Starrett, J. E., Parker, M. F., Xie, K. M., Bronson, J. J., Marcin, L. R., McElhone, K. E., Bergstrom, C. P., Mate, R. A., Williams, R. D., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000239 · Cited by 185 · see citing works
Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., der Auwera, I. V., LEUVEN, F. V., Sugawara, M., Weingertner, M.-C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703137104 · Cited by 176 · see citing works
Cholinesterase Inhibitors for Alzheimer's Disease
Stahl, S. M. (1998) · Hospital Practice · doi:10.3810/hp.1998.11.117 · Cited by 163 · see citing works
RAGE Ligation Affects T Cell Activation and Controls T Cell Differentiation
Chen, Y., Akirav, E. M., Chen, W., Henegariu, O., Moser, B., Desai, D. D., Shen, J. M., Webster, J. C., Andrews, R. C., Mjalli, A. M. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.4272 · Cited by 148 · see citing works
D’Andrea, M. R., & Nagele, R. G. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775474224 · Cited by 147 · see citing works
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
Vandenberghe, R. R., Riviere, M., Caputo, A., Sóvágó, J., Maguire, R. P., Farlow, M. R., Marotta, G., Sánchez‐Valle, R., Scheltens, P., Ryan, J. M., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.003 · Cited by 146 · see citing works
Gamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?
Bursavich, M. G., Harrison, B. A., & Blain, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01960 · Cited by 141 · see citing works
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Burstein, A. H., Grimes, I., Galasko, D. R., Aisen, P. S. S., Sabbagh, M. N., & Mjalli, A. M. M. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-12 · Cited by 137 · see citing works
Scott, J. D., Li, S. W., Brunskill, A., Chen, X., Cox, K., Cumming, J., Forman, M., Gilbert, E., Hodgson, R., Hyde, L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00307 · Cited by 137 · see citing works
Cai, J., Qi, X., Kociok, N., Skosyrski, S., Emilio, A., Ruan, Q., Han, S., Liu, L., Chen, Z., Bowes Rickman, C., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101084 · Cited by 136 · see citing works
Eketjäll, S., Janson, J., Kaspersson, K., Bogstedt, A., Jeppsson, F., Fälting, J. M., Haeberlein, S. B., Kugler, A. R., Alexander, R. C., & Cebers, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150834 · Cited by 132 · see citing works
Funamoto, S., Morishima‐Kawashima, M., Tanimura, Y., Hirotani, N., Saido, T. C., & Ihara, Y. (2004) · Biochemistry · doi:10.1021/bi049399k · Cited by 131 · see citing works
Development of AFFITOPE vaccines for Alzheimer's disease (AD) — From concept to clinical testing
Schneeberger, A., Mandler, M., Otava, O., Zauner, W., Mattner, F., & Schmidt, W. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0070-5 · Cited by 130 · see citing works
Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., & Wischik, C. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219352 · Cited by 128 · see citing works
Harrington, C. R., Storey, J. M. D., Clunas, S., Harrington, K. A., Horsley, D., Ishaq, A., Kemp, S. J., Larch, C. P., Marshall, C., Nicoll, S. L., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.616029 · Cited by 107 · see citing works
Pasquier, F., Sadowsky, C., Holstein, A. R., Prince, G. L., Peng, Y., Jackson, N. M., Fox, N. C., Ketter, N., Liu, E., Ryan, J. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150376 · Cited by 105 · see citing works
Autophagy in Neurodegenerative Diseases and Metal Neurotoxicity
Zhang, Z., Miah, M. R., Culbreth, M. E., & Aschner, M. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1844-x · Cited by 101 · see citing works
Panza, F., Solfrizzi, V., Imbimbo, B. P., Tortelli, R., Santamato, A., & Logroscino, G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.883921 · Cited by 97 · see citing works
Stützer, I., Selevsek, N., Esterházy, D., Schmidt, A., Aebersold, R., & Stoffel, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444703 · Cited by 82 · see citing works
Identification and biology of β‐secretase
Kandalepas, P. C., & Vassar, R. J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07512.x · Cited by 79 · see citing works
β-Secretase: its biology as a therapeutic target in diseases
Wang, H., Li, R., & Shen, Y. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.008 · Cited by 74 · see citing works
Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy
Maelicke, A., Hoeffle-Maas, A., Ludwig, J., Maus, A. D. J., Samochocki, M., Jordis, U., & Koepke, A. K. E. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9269-5 · Cited by 73 · see citing works
Memantine in dementia: a review of the current evidence
Herrmann, N., Li, A., & Lanctôt, K. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.558006 · Cited by 69 · see citing works
de Matos, A. M., Macedo, M. P., & Rauter, A. P. (2017) · Medicinal Research Reviews · doi:10.1002/med.21440 · Cited by 66 · see citing works
New Aminoimidazoles as β-Secretase (BACE-1) Inhibitors Showing Amyloid-β (Aβ) Lowering in Brain
Gravenfors, Y., Viklund, J., Blid, J., Ginman, T., Karlström, S., Kihlström, J., Kolmodin, K., Lindström, J., von Berg, S., von Kieseritzky, F., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300991n · Cited by 65 · see citing works
BACE1 as a Therapeutic Target in Alzheimer’s Disease: Rationale and Current Status
Evin, G. M., & Hince, C. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0099-3 · Cited by 60 · see citing works
Solanezumab: too late in mild Alzheimer's disease?
Neurology, T. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30395-7 · Cited by 58 · cited 1× · see citing works
“Unfortunately, in November 2016, Eli Lilly announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial [65].”
BackgroundLai, R. Y. K., Albala, B., Kaplow, J. M., Aluri, J., Yen, M., & Satlin, A. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.237 · Cited by 57 · see citing works
Porrini, V., Lanzillotta, A., Branca, C., Benarese, M., Parrella, E., Lorenzini, L., Calzà, L., Flaibani, R., Spano, P., Imbimbo, B. P., et al. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.029 · Cited by 53 · see citing works
E2012-Induced Cataract and Its Predictive Biomarkers
Nakano-Ito, K., Fujikawa, Y., Hihara, T., Shinjo, H., Kotani, S., Suganuma, A., Toyohiko, A. O. K. I., & Tsukidate, K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft224 · Cited by 52 · see citing works
Barbier, A. J., Hilhorst, M., Vliet, A. V., Snyder, P., Palfreyman, M. G., Gawryl, M., Dgetluck, N., Massaro, M., Tiessen, R., Timmerman, W., et al. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.013 · Cited by 51 · see citing works
Cu(II) enhances the effect of Alzheimer’s amyloid-β peptide on microglial activation
Yu, F., Gong, P., Hu, Z., Qiu, Y. L., Cui, Y., Gao, X., Chen, H., & Li, J. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0343-3 · Cited by 46 · see citing works
Aβ46 Is Processed to Aβ40 and Aβ43, but Not to Aβ42, in the Low Density Membrane Domains
Yagishita, S., Morishima‐Kawashima, M., Ishiura, S., & Ihara, Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707103200 · Cited by 46 · see citing works
Yu, Y., Logovinsky, V., Schuck, E. L., Kaplow, J. M., Chang, M., Miyagawa, T., Wong, N., & Ferry, J. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.249 · Cited by 45 · see citing works
Gault, L. M., Lenz, R. A., Ritchie, C. W., Meier, A., Othman, A. A., Tang, Q., Berry, S. M., Pritchett, Y., & Robieson, W. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0210-1 · Cited by 43 · see citing works
Bhattacharya, S., Maelicke, A., & Montag, D. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142421 · Cited by 39 · see citing works
Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment
Montoliu‐Gaya, L., & Villegas, S. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.11 · Cited by 37 · see citing works
P1‐236: E2012: A novel gamma‐secretase modulator‐pharmacology part
Hashimoto, T., Ishibashi, A., Hagiwara, H., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.787 · Cited by 29 · see citing works
Semagacestat's fall: where next for AD therapies?
(2013) · Nature Medicine · doi:10.1038/nm.3365 · Cited by 24 · see citing works
Arai, H., Suzuki, H., Yoshiyama, T., Lobello, K., Peng, Y., Liu, E., Ketter, N., Margolin, R. A., Jackson, N. M., & Fujimoto, Y. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.564 · Cited by 18 · see citing works
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma
McQuade, J. L., Posada, L., Lecagoonporn, S., et al. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000296 · Cited by 18 · see citing works
Albala, B., Kaplow, J. M., Lai, R. Y. K., Matijevic, M., Aluri, J., & Satlin, A. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.08.023 · Cited by 16 · see citing works
New Hydroxyquinoline‐Based Derivatives as Potent Modulators of Amyloid‐β Aggregations
Fu, C., Hsu, L., Liao, Y., & Hu, M. (2016) · Archiv der Pharmazie · doi:10.1002/ardp.201500453 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Na, R., Yang, J.-H., Yeom, Y., Kim, Y. J., Byun, S., Kim, K., & Kim, K. W. (2019) · Psychiatry Investigation · doi:10.30773/pi.2019.02.11.2 · Cited by 70 · see citing works
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works
“Tideglusib (NP-031112 (labeled as 13 , Figure 5)), an inhibitor of GSK3 β , targets tau hyperphosphorylation, which is required for the development of tau tangles [171–173].”
BackgroundMeilandt, W. J., Maloney, J. A., Imperio, J., Lalehzadeh, G., Earr, T., Crowell, S., Bainbridge, T. W., Lu, Y., Ernst, J. A., Fuji, R. N., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0553-5 · Cited by 45 · see citing works
- Authors
- Lao, K., Ji, N., Zhang, X., Qiao, W., Tang, Z., & Gou, X.
- Affiliations
- Xi'an Medical University (CN)
- Shaanxi University of Chinese Medicine (CN)
- Corresponding author
- Tang, Zhishu
- Gou, Xingchun
- Venue
- Journal of drug targeting
- Publisher
- Informa UK Limited
- Published
- 2018-06-20
- Volume
- 27
- Issue
- 2
- Pages
- 164-173
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- 1029-2330
- OpenAlex
- W2802641570
- Cited by
- 86
- References
- 95
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 8 · 2023: 11 · 2022: 9 · 2021: 14 · 2020: 14 · 2019: 14 · 2018: 3 · 2012: 1
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of drug targeting (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NSFC (81471415, 17JK0666)
- Shaanxi Provincial Education Department
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, drug development, acetylcholinesterase inhibitors, memantine, cholinergic system, alpha7 nicotinic acetylcholine receptor, NMDA receptor, beta-secretase, γ-secretase modulators, tau protein, neuroinflammation, glucagon-like peptide-1, drug discovery, clinical trial failure
- MeSH terms
- Drug Development, Alzheimer Disease, Central Nervous System Agents, Humans, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
